Chondroitin sulfate proteoglycan 4 (CSPG4) has been demonstrated to exhibit aberrant expression in various tumor types, including soft tissue sarcoma, squamous cell carcinoma of the head and neck, breast cancer, and anaplastic thyroid cancer. This evidence concerns the gene CSPG4 and thyroid gland undifferentiated (anaplastic) carcinoma.